MacroArray Diagnostics GmbH to announce Allergy Explorer ALEX2

The new version will open the next chapter in IgE testing.

Allergy Explorer is the first in vitro multiplex allergy test allowing simultaneous measurement of total IgE (tIgE) and specific IgE (sIgE) against a plethora of allergen extracts and molecular allergens.

Based on our test panel composition of allergen extracts and molecular allergens, a near complete picture of each patient’s sensitization status is obtained. ALEX2 is based on our proprietary nano-bead technology. Every allergen (extract) can be individually optimized for production.The flexible analysis software, allows our customers to analyze tailormade allergen panels as they see fit for their clinical needs – Multiplex on demand.

The ALEX2 assay protocol integrates a powerful Cross-reactive Carbohydrate Determinants (CCDs) inhibitor during serum incubation, which will clear up your specific IgE results. This reduces the interpretative burden for physicians of CCD positive patients and increases the specificity of our test results. Simultaneous measurement of total and specific IgE Near-complete allergen panel, individually optimized Multiplex test with on-demand panel composition Integrated CCD inhibition

About Macro Array Diagnostics

Macro Array Diagnostics is a Vienna-based MedTech company. We develop, produce and distribute tests, instruments and software for allergy diagnostics and research applications. Our products allow flexible, reliable and affordable sensitization profiling of each patient. Our multidisciplinary team ensures that customers receive the most advanced tools to fulfill their diagnostic needs. For more information visit: 

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)